Intranasal Neuropeptide Y (NPY) for Depression and PTSD: The Evidence Biohackers Are Missing

Of all the peptides discussed in biohacking communities, neuropeptide Y (NPY) receives surprisingly little attention. This is puzzling because it has something most other peptides lack: randomized controlled trial data from Western researchers published in major journals.

What Is Neuropeptide Y?

NPY is one of the most abundant neuropeptides in the brain. It plays crucial roles in stress response, anxiety, appetite, and emotional regulation. Low NPY levels have been associated with increased vulnerability to stress and PTSD.

Research interest in NPY for psychiatric applications stems from observations that individuals with higher NPY levels show greater stress resilience. The hypothesis is that supplementing NPY might enhance stress coping and reduce depression and anxiety symptoms.

The Depression Trial

A 2020 randomized controlled trial published in the International Journal of Neuropsychopharmacology examined intranasal NPY (6.8 mg) in 30 patients with major depressive disorder.

The results showed superiority over placebo at 24 hours post-administration. The Montgomery-Asberg Depression Rating Scale (MADRS) reduction was -10.3 with NPY versus -5.6 with placebo, yielding a medium effect size (Cohen’s d = 0.67).

Notably, the primary endpoint at 48 hours was not significant. The effect emerged at 5 hours and peaked at 24 hours, suggesting a therapeutic window that may require optimization through repeated dosing.

The PTSD Trial

A 2018 dose-ranging study published in the same journal examined intranasal NPY in 26 patients with posttraumatic stress disorder. Participants received escalating doses up to 9.6 mg.

NPY was well-tolerated at all doses tested. Higher doses showed greater treatment effects on Beck Anxiety Inventory scores following trauma script provocation (F1,20 = 4.95, P = .038).

Why Is NPY Overlooked?

Given this evidence, why is NPY not more popular in biohacking circles? Several factors likely contribute: availability (NPY is harder to source than Selank, Semax, or BPC-157); marketing (companies selling peptides have not promoted NPY as heavily); dosing complexity (the trials used relatively high doses that may be impractical); and community effects (biohacking trends are driven more by influencer enthusiasm than by evidence quality).

My Clinical Perspective

NPY is a case study in how evidence quality and popularity can diverge in the peptide space. It has better controlled trial data than Selank or BPC-157, yet receives a fraction of the attention.

For patients specifically interested in evidence-based peptide options for depression or PTSD, NPY deserves consideration. The challenge is practical access and the need for further research on dosing protocols.

This peptide illustrates why critically evaluating evidence matters more than following community trends.